ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease
April 07, 2021Syndax Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with chronic graft versus host disease (cGVHD).
Pharma Sources Insight January 2025
